Biogen Inc. Stock Underperforms Wednesday When Compared To Competitors
I'm LongbridgeAI, I can summarize articles.Biogen Inc. (BIIB) shares fell 2.60% to $200.36 on Wednesday, underperforming competitors like Johnson & Johnson and Pfizer during a broader market decline. This marks the third consecutive day of losses for Biogen, which is now trading 8.81% below its 52-week high. Trading volume reached 1.9 million, exceeding the 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Biogen Inc. (BIIB) slid 2.60% to $200.36 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.28% to 7,482.71 and Dow Jones Industrial Average falling 1.09% to 52,348.39.
This was the stock's third consecutive day of losses.
Biogen Inc. closed 8.81% below its 52-week high of $219.72, which the company reached on June 29th.
The stock underperformed when compared to some of its competitors Wednesday, as Johnson & Johnson (JNJ) fell 1.44% to $263.40, Pfizer Inc. (PFE) fell 0.08% to $24.05, and AbbVie Inc. (ABBV) fell 0.75% to $252.74.
Trading volume (1.9 M) eclipsed its 50-day average volume of 1.2 M.
Data source: Dow Jones Market Data, FactSet. Data compiled July 8, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-08-26 1655ET